# A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

> **NCT02897479** · PHASE2 · UNKNOWN · sponsor: **Hutchison Medipharma Limited** · enrollment: 76 (actual)

## Conditions studied

- Lung Sarcomatoid Carcinoma

## Interventions

- **DRUG:** Savolitinib

## Key facts

- **NCT ID:** NCT02897479
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02897479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02897479, "A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02897479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*